THE WORLD’S LEADER IN FIGHTING OVARIAN CANCER

ANNUAL REPORT 2022
Dear Friends,

This past year was one of amazing growth for OCRA as we continued our fight against ovarian and related gynecologic cancers. We helped more people than ever navigate life with cancer and made real legislative headway, while our grantees worked with laser focus to find better treatments and a cure for this devastating disease.

In laboratories nationwide, researchers explored the intricacies of ovarian cancer, making significant advancements. Our strong community of patients, survivors and loved ones tapped into profound reservoirs of resilience, providing unwavering support to each other and contributing their voices to the ongoing battle. Concurrently, our dedicated advocates used their voices on behalf of everyone impacted by this disease. Together we strove to maintain our forward momentum and unravel the complexities of ovarian cancer, while enhancing the range of support services for our community.

Calls to our patient support line grew exponentially in 2022, as did interest in our support programs. To meet the need, we launched several new Staying Connected support groups and maximized our resources, continuing our oncology social work student program in partnership with Smith College and Columbia University Schools of Social Work.

OCRA's Survivors Teaching Students program further expanded our reach to the next generation of healthcare providers, adding 24 new schools to its roster. And our two virtual Advocacy Days resulted in an extraordinary 258 meetings with congressional offices.

Our mission is nothing short of curing ovarian cancer, and I’m heartened to share that OCRA grantees made exceptional progress this year, tackling the most critical challenges of this disease, uncovering promising therapeutic targets and paths to better prevention, using machine learning to bridge gaps and better predict response to treatment, and so much more.

Through it all, you stood beside us. As we reflect on the year and look with optimism toward the future, we are grateful to each and every one of you, for your dedication, your support, and your shared commitment to building a world free from ovarian cancer.

The highlights in this report will give you a topline look at our programs and impact. Please visit our website (ocrahope.org) or follow us on social media (@ocrahope) to stay up to date. On behalf of the entire team at Ovarian Cancer Research Alliance, thank you.

Sincerely,

Audra Moran
President & CEO, OCRA
BY THE NUMBERS

2022

Funded 22 scientists $6.7M

Advocates influenced a federal investment of $256M

7 action alerts resulted in 10,113 messages to Congress

Advocates represented 113 advocate leaders 42 states & D.C.

975+ trained volunteers reached 10,417

50% increase from year prior

Rising healthcare professionals at 393 schools

WOMAN TO WOMAN mentors assisted 516 patients around the U.S.

78,000+ members in our inspire online community

2,000+ attendees of our virtual support programs for the community

People from the U.S. and around the world attended our ovarian cancer national conference

627
RESEARCH

PARTNERING WITH RESEARCHERS TO DEFEAT OVARIAN CANCER
As the largest non-government funder of ovarian cancer research, OCRA is at the forefront of scientific discovery. To date, we have invested over $116M in bold and promising initiatives that propel the collective field forward and bring hope for a cure. With support from OCRA, our grantees are making critical advances toward better treating, preventing and ultimately curing ovarian cancer.

2022 OCRA GRANTEES:

- Studied how frequent use of aspirin is associated with a reduction in ovarian cancer.
- Used machine learning to bridge the gap between disparate data sets specifically in patients with HGSOC.
- Investigated how knocking out KDM5A relates to an increased presence and activation of cancer-killing immune cells.
- Discovered a tool to aid in selecting the best treatment options.
- Dosed the first patients in the clinical trial “Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)”
- Studied how partner proteins may contribute to ovarian cancer tumor growth.
- Found key proteins in HGSOC cancer cells and explored combined treatment option that resulted in smaller tumors and longer survival.
- Discovered a genetic link between ovarian cancer subtypes and endometriosis.
- Studied BRCA mutations for potential to further predict ovarian cancer in patients.
COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Benjamin Bitler, PhD  
*University of Colorado Denver*  
A machine learning approach to chemotherapy-induced remodeling of the tumor

Ronald Buckanovich, MD, PhD  
*Magee-Womens Research Institute & Foundation*  
Role of macrophage-secreted BIGH3 in tumor immunity

Jen-Tsan Chi, MD, PhD  
*Duke University School of Medicine*  
The role of ferroptosis in the metastatic ovarian cancer

Sohrab Shah, PhD  
*Memorial Sloan Kettering Cancer Center*  
Inferring mutational processes and patient stratification from standard-of-care clinical imaging (*in collaboration with Microsoft AI for Health*)

LIZ TILBERIS EARLY CAREER AWARD

Chi Lam Au Yeung, PhD  
*MD Anderson Cancer Center*  
Cancer-derived exosomal miRNAs modulate ovarian tumor microenvironment

Maria Victoria Botuyan, PhD  
*Mayo Clinic, Rochester, MN*  
Probing how RAD18 and BARD1 antagonize 53BP1 in HR DNA repair
Lindsay Brubaker, MD  
*University of Colorado Denver*  
Targeting Chromobox 2 to overcome macrophage-induced immune suppression

Sammy Ferri-Borgogno, PhD  
*MD Anderson Cancer Center*  
BRCA-deficient ovarian cancer and IFITM3: a new “power couple”

Livnat Jerby, PhD  
*Stanford University*  
Targeting multifactorial immune evasion mechanisms in ovarian cancer

Jasmine Plummer, PhD  
*Cedars-Sinai Medical Center*  
Chemopreventative targets in BRCA1 carrier models with P53 lesions (*Gail Baird Research Grant Recipient*)

Haineng Xu, PhD  
*University of Pennsylvania*  
Strategies to exploit genetic alterations in clear-cell ovarian cancer

**ANN AND SOL SCHREIBER MENTORED INVESTIGATOR AWARD**

Gamze Bildik Elcik, PhD  
*MD Anderson Cancer Center*  
DIRAS3 inhibits KRAS and sensitizes LGSOC cells to anti-autophagic therapy

Melica Brodeur, MD  
*Memorial Sloan Kettering Cancer Center*  
Exploiting SMARCA4 alterations for new therapeutics in ovarian cancers

Patrick Innamarato, PhD  
*H. Lee Moffitt Cancer Center*  
Determination of the immunogenic antigen repertoire in ovarian cancer

Benjamin Johnson, PhD  
*Van Andel Research Institute*  
Ovarian cancer stem-like cell differentiation trajectories in single cells
OCRA’s 2022 grantees targeted a range of important issues, reflecting the complexity of this disease. Their studies focused on discovering more effective options for treating several types of ovarian cancer, including rare subtypes, and recurrent metastatic tumors that have become resistant to current therapies; exploring immunotherapy’s potential; investigating disease origins; working toward more personalized therapies; and harnessing cutting-edge technologies for molecular tumor profiling and data sharing that can accelerate progress across the entire ovarian cancer field.
ADVOCACY

ENGAGING WITH POLICYMAKERS TO KEEP THIS FIGHT A PRIORITY
OCRA is the leading voice advocating on behalf of the ovarian cancer community, working with elected officials to protect federal research and education, patient safety, and access to high-quality care for those impacted by the disease.

In 2022, we held a virtual Advocacy Day in March where 218 advocates from 45 states met with 258 congressional offices to push for expanded federal funding for ovarian cancer research and awareness programs.

OCRA pushed for improved access to clinical trials with the DIVERSE Trials Act (H.R.5030/S.2706) and sought to make genetic testing more readily available with the Reducing Hereditary Cancer Act (H.R.4110/S.3656).

Our targeted legislative campaigns helped lead to a federal government spending of $256 million on ovarian cancer research and awareness programs.

Our Advocate Leaders program grew from 101 members to 113 members representing 42 states and the District of Columbia.

In addition, we sent out seven Action Alerts, resulting in 10,113 messages to Congress.
We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students® program.

In 2022 we continued our return to in-person presentations post-pandemic, with approximately 30% of our 382 presentations involving our volunteers’ return to classrooms.

We continued our efforts to expand our reach and bring patient and caregiver voices to more historically Black colleges and universities, presenting the program for the first time at Charles R. Drew University of Medicine and Science in Los Angeles and Morehouse School of Medicine in Georgia.

We trained 64 new volunteers, bringing our team to 976 individuals committed to sharing their stories of diagnosis and treatment with 10,401 rising medical professionals at 393 schools and institutions around the U.S.
PATIENT SUPPORT
STANDING WITH EVERYONE IMPACTED BY OVARIAN & GYNECOLOGIC CANCERS
Our support programs are a lifeline for patients and families navigating ovarian cancer. From our Woman to Woman peer support program that pairs patients with trained survivor mentors, to our informative National Conference and social worker-facilitated virtual support series, we’re lifting up our community with hope and resources while we strive for a cure.

Calls to our patient support line grew significantly this year, totaling 1717 calls, a 50% increase from 2021. To meet the need, we continued our Oncology Student Field Placement with students from Smith & Columbia Schools of Social Work. A student from our 2021 cohort is now a full-time Gynecologic Oncology Social Worker at Memorial Sloan Kettering Cancer Center.

We paired 516 gynecologic cancer patients with 392 Woman to Woman mentors, who lend support and friendship in a way that only those with shared experience can offer.

Additionally, OCRA expanded its Staying Connected support series to over 2,000 attendees, offering three weekly groups and three monthly groups, creating a support community around issues of new diagnosis, recurrence, sexual intimacy, end of life, and one specifically for loved ones. We expanded our Express Yourself program, combining themed therapeutic creative activities with facilitated discussion, to 387 people registered.
Our patient support team also oversaw the growth of our OCRA Inspire Online Community, which comprises more than 78,000 members worldwide.

We hosted our annual Ovarian Cancer National Conference during Ovarian Cancer Awareness Month, welcoming more than 625 attendees from eight countries. Held virtually, our conference gave patients, survivors, loved ones and healthcare providers the opportunity to hear directly from experts in the field about what’s new and promising in ovarian cancer research, treatment and care, and provided invaluable opportunities to connect with others in the community.
BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

John Orrico, Chair
Matthew Miller, Vice President
Robin Cohen, Secretary
Mark Tessar, Treasurer
Tom Liebman, At-Large

BOARD MEMBERS

Jeannette Chang
Carmel Cohen, MD*
Mei-Li da Silva Vint, Esq.
Andy Feuerstein, Esq.
Carol Hamilton
John W. Hansbury, Esq.*
Caroline Hirsch
Veronica Jordan, PhD
Dana L. Mark, Esq.*
Chris Newcomb
Lisa Schreiber
Elle Simone Scott
Chris Tilberis

*Emeritus Executive Committee Member

as of February 2024
SCIENTIFIC ADVISORY COMMITTEE

as of February 2024

Ronald Alvarez, MD, MBA, CHAIR (2016-present)
Vanderbilt University Medical Center, Nashville, TN

Deborah Armstrong, MD (2016-present)
Johns Hopkins School of Medicine, Baltimore, MD

Robert C. Bast, Jr., MD (1997-present)
MD Anderson Cancer Center, Houston, TX

Andrew Berchuck, MD, (2000-present)
Duke Comprehensive Cancer Center, Durham, NC

Jonathan S. Berek, MD, MMS (1997-present)
Stanford University School of Medicine, Palo Alto, CA

Molly Brewer, DVM, MD, MS (2004-present)
University of Connecticut Health Center, Farmington, CT

Ronald Buckanovich, MD, PhD (2013-present)
Magee-Womens Research Institute, Pittsburgh, PA

Kathleen Cho, MD (2022-present)
University of Michigan Medical School, Ann Arbor, MI

Robert Coleman, MD (2016-present)
Vaniam Group

Oliver Dorigo, MD, PhD (2023-present)
Stanford University, Palo Alto, CA

Annie Ellis (2016-present)
Research Advocate

Katherine Fuh, MD, PhD (2021-present)
University of California, San Francisco, San Francisco, CA

Ellen Goode, PhD (2019-present)
Mayo Clinic, Rochester, NY

Gillian E. Hanley, PhD (2022-present)
University of British Columbia, Vancouver, Canada

Beth Karlan, MD (2019-present)
UCLA Medical Center, Los Angeles, CA

Dineo Khabele, MD (2015-present)
Washington University School of Medicine, St. Louis, MO

Susan Leighton, MA (2021-present)
Research Advocate

Ernst Lengyel, MD, PhD (2013-present)
The University of Chicago, Chicago, IL

Ursula Matulonis, MD, GRANTS OVERSIGHT CHAIR (2014-present)
Dana-Farber Cancer Institute, Boston, MA

Kathleen Moore, MD, MS (2021-present)
The University of Oklahoma, Oklahoma City, OK

Carolyn Muller, MD, FACOG (2021-present)
The University of New Mexico, NM

Kenneth Nephew, PhD (2014-present)
Indiana University, Bloomington, IN

Kunle Odunsi, MD, PhD (2014-present)
The University of Chicago, Chicago, IL

Sandra Orsulic, PhD (2011-present)
David Geffen School of Medicine at UCLA, Los Angeles, CA

Celeste Leigh Pearce, PhD, MPH (2015-present)
University of Michigan, Ann Arbor, MI

Stephen Rubin, MD (2000-present)
Fox Chase Cancer Center, Philadelphia, PA

Carolyn D. Runowicz, MD (1997-present)
Florida International University, Miami, FL

Ie-Ming Shih, MD, PhD (2013-present)
Johns Hopkins University School of Medicine, Baltimore, MD

Anil Sood, MD (2016-present)
MD Anderson Cancer Center, Houston, TX

Shelley Tworoger, PhD (2019-present)
Oregon Health & Science University, Portland, OR

Jason Wright, MD (2021-present)
Columbia University Medical Center, NY, NY
STAFF

Audra Moran
President & CEO

Erin Cassin
Senior Manager, Social Media & Content

Nancy Cincotta, LCSW, MPhil
Director, Social Work Education & Research (Consultant)

Jenny Daugherty
Development Coordinator

Sarah DeFeo
Chief Program Officer

Sarah Handsman, LCSW
Oncology Social Worker

Jessica Hughson-Andrade
Director, Strategic Alliances

Emily Hynes
Program Associate

Susan Leighton
National Program Director, Survivors Teaching Students (Consultant)

Kim Liao
Senior Development Associate

Diana Maynard
Associate Director, Events

Kristin McGowan
Director, Grants & Scientific Affairs

Tracy Moore, LCSW
Vice President, Support & Education

Josephine Neil
Operations & Finance Associate

Ginika Nwaba
Ann Kolker Health Policy Fellow

Brian Phair
Director, Donor Relations

Chad Ramsey
Vice President, Policy

Julia Thayer
Associate Director, Advocacy

Nikki Wargo
Vice President, Philanthropic Partnerships & Community Engagement

Lindsey Weeks
Director, Digital Communications

Jon Zeidman
Chief Development Officer

as of February 2024
# FINANCIAL STATEMENT

## 2022

<table>
<thead>
<tr>
<th>Total Revenue &amp; Support</th>
<th>$13,648,681</th>
</tr>
</thead>
</table>

### Expenses

<table>
<thead>
<tr>
<th>Program Services</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$7,300,143</td>
</tr>
<tr>
<td>Conference</td>
<td>$532,402</td>
</tr>
<tr>
<td>Education, Support and Advocacy</td>
<td>$1,789,378</td>
</tr>
</tbody>
</table>

### Total Program Services

<table>
<thead>
<tr>
<th>Total Program Services</th>
<th>$9,621,923</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Fundraising</th>
<th>$1,442,482</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Administrative</th>
<th>$894,405</th>
</tr>
</thead>
</table>

### Total Expenses

<table>
<thead>
<tr>
<th>Total Expenses</th>
<th>$11,958,810</th>
</tr>
</thead>
</table>

### Ending Net Assets

<table>
<thead>
<tr>
<th>Ending Net Assets</th>
<th>$22,830,266</th>
</tr>
</thead>
</table>

### REVENUE BREAKDOWN

- Individuals (28%)
- Foundations (5%)
- Corporate (4%)
- Industry (6%)
- Events (14%)
- Bequests (59%)
- Investment (-19%)*
- Other (4%)

* Investment revenue includes $3,296,480 of unrealized losses in market value.